The present invention relates to novel chromone alkaloid of formula 1 isolated from the plant Dysoxylum binectariferum. The compound 5,7-dihydroxy-6-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4H-chromen-4-one, is found to be a potential inhibitor of cell growth and proliferation and also inhibits production of pro-inflammatory cytokines. The formulations of this particular compound can be used for treatment of cancer and inflammation. ##STR00001##

Methods, compositions, and kits are provided for synthesizing bioactive chromane, the method including: constructing a tertiary ether stereocenter enantioselectively by catalyzed alkynylation of a substituted chromenone to obtain a chromanone; reducing alkyne and ketone in the chromanone to obtain a chroman; and converting ester to methyl group thereby obtaining chromane.

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: ##STR00001## wherein: X is OH, C.sub.1-C.sub.6 alkoxyl; Y and Z are independently selected form a C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxyl, halogen, un-substituted or C.sub.1-C.sub.6 substituted amine, .sup.18F, .sup.19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: ##STR00001## wherein: X is OH, C.sub.1-C.sub.6 alkoxyl; Y and Z are independently selected form a C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxyl, halogen, un-substituted or C.sub.1-C.sub.6 substituted amine, .sup.18F, .sup.19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

The present disclosure relates to a method of treating at least one Cell-Associated Neurotoxicity Syndrome (ICANS), cancer-related cognitive impairment, Infusion Reaction Syndrome (IRS), Capillary Leak Syndrome (CLS), Tumor Lysis Syndrome (TLS), Macrophage Activation Syndrome (MAS), Systemic Inflammatory Response Syndrome (SIRS), Immune Reconstitution Inflammatory Syndrome (IRIS), Graft-Versus-Host Disease (GVHD), Acute Respiratory Distress Syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, Systemic Inflammatory Response Syndrome (SIRS), and Immune-related Adverse Events Syndrome (IrAES) in a subject in need thereof, comprising administering a mast cell stabilizer or a compound of Formula I or Formula II: Formula I, Formula II, wherein R.sup.1 is halogen, OH, or —OC(O)C.sub.1-5alkyl R.sup.2 and R.sup.3 are each independently selected from CO.sub.2R.sup.4 or CH.sup.2OR.sup.5; R.sup.4 is i L, Na, K, H, C.sub.1-5alkyl, or —CH.sub.2CO(C.sub.1-5alkyl); and R.sup.5 is H or C(O)(C.sub.1-5alkyl), or a pharmaceutically acceptable salt thereof.

##STR00001##

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

Described herein are compounds and methods of treating or imaging a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of a cromolyn ester.